Re-appointment of Cost Auditor
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anuh Pharma's Board approved FY26 audited results showing revenue of Rs. 77,165.74 Lakhs, up 16.6% YoY from Rs. 66,151.49 Lakhs. However, profit after tax declined to Rs. 4,104.61 Lakhs from Rs. 4,735.19 Lakhs in FY25. EBITDA margin compressed to 8.56% from 10.64% in the previous year. The Board recommended a dividend of Rs. 1.50 per share (30% payout), subject to shareholder approval at the AGM on August 12, 2026. Additionally, 9 shareholders holding ~0.95% stake have requested re-classification from Promoter Group to Public category, and the company appointed new Internal Auditors (RMJ & Associates LLP) and re-appointed the Cost Auditor (Ankit Kishor Chande) for FY27.
Revenue growth is positive but profit decline and margin compression may concern investors. The promoter group reclassification requests, though small (0.95%), could slightly alter the promoter-public shareholding dynamics. The unchanged auditor opinion is a positive signal for financial transparency.